VDPHL01 for alopecia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 11 Mar 2025: Trial started, NCT06972264
  2. 14 May 2025: Trial registered, NCT06972264

The trials

NCT06527365: Safety and Efficacy of VDPHL01 in Males and Females With AGA

State
Under way
Phase
Phase 2
People
70 planned
Started
8 Jul 2024
Primary completion
Aug 2026
Arms
VDPHL01 Tablet
Results
None posted
  1. 8 Jul 2024: Trial started
  2. 30 Jul 2024: Trial registered

NCT06724614: Efficacy and Safety of VDPHL01 in Males With AGA

State
Under way
Phase
Phase 2 and Phase 3
People
480 planned
Started
6 Nov 2024
Primary completion
Feb 2026
Arms
VDHPL01 BID, VDPHL01 QD and Placebo QD
Results
None posted
  1. 6 Nov 2024: Trial started
  2. 9 Dec 2024: Trial registered

NCT06972264: Safety and Efficacy of VDPHL01 in Males With AGA

State
Under way
Phase
Phase 3
People
480 planned
Started
11 Mar 2025
Primary completion
Dec 2026
Arms
VDHPL01 BID, VDPHL01 QD and Placebo QD
Results
None posted
  1. 11 Mar 2025: Trial started
  2. 14 May 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.